Gotoh Minoru, Kaminuma Osamu
Department of Otorhinolaryngology, Nippon Medical School, Tokyo 113-8603, Japan.
Laboratory of Allergy and Immunology, The Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Pathogens. 2021 Feb 2;10(2):147. doi: 10.3390/pathogens10020147.
Owing to the successful application of sublingual immunotherapy (SLIT), allergen immunotherapy (AIT) has become one of the leading treatments for allergic diseases. Similar to the case with other AITs, such as subcutaneous and oral immunotherapies, not only the alleviation of allergic symptoms, but also the curing of the diseases can be expected in patients undergoing SLIT. However, how and why such strong efficacy is obtained by SLIT, in which allergens are simply administered under the tongue, is not clearly known. Various potential mechanisms, including the induction of blocking antibodies, T cell tolerance, regulatory B and T cells, CD103CD11b classical dendritic cells, and CD206 macrophages, and the reduction of innate lymphoid cells, mast cells, and basophils, have been suggested. Recently, through a comparative analysis between high- and non-responder patients of SLIT, we have successfully proposed several novel mechanisms. Here, we introduce our recent findings and summarize the current understanding of the mechanisms underlying the strong efficacy of SLIT.
由于舌下免疫疗法(SLIT)的成功应用,变应原免疫疗法(AIT)已成为过敏性疾病的主要治疗方法之一。与其他AITs(如皮下和口服免疫疗法)的情况类似,接受SLIT治疗的患者不仅可以预期过敏症状得到缓解,而且疾病也能治愈。然而,在SLIT中,变应原只是简单地舌下给药,如何以及为何能获得如此强大的疗效尚不清楚。已经提出了各种潜在机制,包括诱导阻断抗体、T细胞耐受、调节性B细胞和T细胞、CD103CD11b经典树突状细胞和CD206巨噬细胞,以及减少先天性淋巴细胞、肥大细胞和嗜碱性粒细胞。最近,通过对SLIT高反应者和无反应者患者的比较分析,我们成功地提出了几种新机制。在此,我们介绍我们最近的发现,并总结目前对SLIT强大疗效潜在机制的理解。